Pre-vaccination Antibody Titers Against Seasonal Coronaviruses and Antibody Responses to the Pfizer-BioNTech BNT162b2 COVID-19 mRNA Vaccine in Healthcare Workers
Open Forum Infectious Diseases
; 8(SUPPL 1):S323, 2021.
Article
in English
| EMBASE | ID: covidwho-1746553
ABSTRACT
Background. The Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study is following over 200 healthcare workers who have received the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. A major aim of the study is to determine whether baseline antibody titers against the seasonal human coronaviruses are associated with altered levels of vaccine-induced antibody responses to SARS-CoV-2. Methods. Serial serum samples obtained pre-vaccination and 1 month after the second dose were tested for IgG antibodies against the full pre-fusion spike protein and the receptor binding domain (RBD) of SARS-CoV-2, as well as the full pre-fusion spike proteins of OC43, HKU1, 229E, and NL63. Antibodies were measured using highly sensitive and specific multiplex assays based on Luminex-xMAP technology. Results. Preliminary analyses of the first 103 subjects in whom we have 1 month post-vaccination serum demonstrate development of high IgG geometric mean titers (GMT) to both the full spike protein (GMT 13,685, 12,014-15,589, 95% CI) and the RBD (GMT 19,448, 17,264-21,908, 95% CI) of SARS-CoV-2 after the 2nd vaccine dose. Preliminary analysis demonstrates no association between baseline antibody titers against spike protein of OC43 and antibody titers against SARS-CoV-2 spike protein (Pearson's r-value= 0.13, P-value= 0.21) or RBD (Pearson's r-value= 0.09, P-value= 0.36) one month after vaccination. Future analyses will evaluate whether there is an association with baseline seasonal coronavirus antibody titers and either SARS-CoV-2 neutralization titers or anti-SARS-CoV-2 spike protein titers at 6 months after vaccination. Conclusion. These preliminary results suggest that baseline antibody responses to seasonal coronaviruses neither boost nor impede SARS-CoV-2 vaccine-induced antibody responses. Longitudinal sampling will enable assessment of vaccine durability and determination of whether baseline seasonal coronavirus antibody levels are associated with altered duration of detectable COVID-19 vaccine-induced antibody responses.
endogenous compound; immunoglobulin G; immunoglobulin G antibody; tozinameran; virus spike protein; adult; antibody response; antibody titer; conference abstract; controlled study; drug therapy; female; health care personnel; human; human experiment; human tissue; immunoglobulin blood level; major clinical study; male; nonhuman; preliminary data; prospective study; protein domain; receptor binding; Severe acute respiratory syndrome coronavirus 2; vaccination
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Open Forum Infectious Diseases
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS